- McConnell Campaign Manager Quits Amid Scandal
- Obama Weighs Delay in Action on Immigration
- Judge Strikes Down Texas Abortion Law
- Neck-and-Neck in Arkansas
- Judge Dismisses McDaniel Challenge
Pfizer Leads Jump in Pharmaceutical Lobbying
Posted at 2:38 p.m. on Oct. 24, 2013
Large pharmaceutical companies may benefit from more customers under the Affordable Care Act, but they still lobby for fewer regulations in order to reduce the cost of bringing a new drug to market.
New York-based Pfizer Inc., the largest research-based pharmaceutical company, reported spending $2,380,000 in the third quarter, up $850,000 (55%) from the $1,530,000 they reported spending in the second quarter of 2013. Pfizer develops and produces vaccines and medicines such as Lipitor, Diflucan, Lyrica, Zithromax, Viagra, and Celebrex.
Pfizer lobbied on issues relating to health care reform, patents, consumer protection and safety, drug abuse, Medicare, taxes, trade, among others.
To search detailed money-in-politics databases, visit Political MoneyLine.